Doxorubicin hydrochloride 2 mg/ML [Adriamycin]
RxNorm 1799302

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1799302 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: doxorubicin hydrochloride 2 mg/ML [Adriamycin].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Doxorubicin hydrochloride 2 mg/ML [Adriamycin]
AUI:12311341
TMSY
DOXOrubicin hydrochloride 2 mg/ML [Adriamycin]
AUI:12383026

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDC

Semantic Branded Drug Component (SBDC):
Doxorubicin hydrochloride 2 mg/ML [Adriamycin]
(Atom ID: 12311341)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
doxorubicin hydrochloride 2 MG/ML [Adriamycin]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1799302
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12311341
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
1799302
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN OBSOLETED
02/24/2026
Date the RxNorm atom became obsolete

TMSY

Tall Man Lettering Synonym (TMSY):
DOXOrubicin hydrochloride 2 mg/ML [Adriamycin]
(Atom ID: 12383026)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
DOXOrubicin hydrochloride 2 MG/ML [Adriamycin]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1799302
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12383026
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
1799302
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Doxorubicin


Doxorubicin is used in combination with other medications to treat certain types of bladder, breast, lung, stomach, and ovarian cancer; Hodgkin's lymphoma (Hodgkin's disease) and non-Hodgkin's lymphoma (cancer that begins in the cells of the immune system); and certain types of leukemia (cancer of the white blood cells), including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML, ANLL). Doxorubicin is also used alone and in combination with other medications to treat certain types of thyroid cancer and certain types of soft tissue or bone sarcomas (cancer that forms in muscles and bones). It is also used to treat neuroblastoma (a cancer that begins in nerve cells and occurs mainly in children) and Wilms' tumor (a type of kidney cancer that occurs in children). Doxorubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of cancer cells in your body.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.